Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Disc Medicine, Inc. and its officers or directors [1] Group 1: Company Overview - Disc Medicine, Inc. is publicly traded on NASDAQ under the ticker symbol IRON [1] - The company is currently facing scrutiny due to a delay in the review timeline of a drug under development, which has raised safety and efficacy concerns flagged by the U.S. Food and Drug Administration [3] Group 2: Stock Performance - Following the news of the FDA's concerns, Disc's stock price experienced a decline of $6.04 per share, representing a 7.84% drop, closing at $71.04 per share on January 15, 2026 [3] Group 3: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4] - The firm has successfully recovered numerous multimillion-dollar damages awards for class members in the past [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Disc Medicine, Inc. and its officers or directors [1] Group 1: Company Overview - Disc Medicine, Inc. is publicly traded on NASDAQ under the ticker symbol IRON [1] - The company is currently facing scrutiny due to a delay in the review timeline of a drug under development, which has raised safety and efficacy concerns flagged by the U.S. Food and Drug Administration [3] Group 2: Stock Performance - Following the news of the FDA's concerns, Disc's stock price experienced a decline of $6.04 per share, representing a 7.84% drop, closing at $71.04 per share on January 15, 2026 [3] Group 3: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Disc Medicine, Inc. and its officers or directors [1] Group 1: Company Overview - Disc Medicine, Inc. is publicly traded on NASDAQ under the ticker symbol IRON [1] - The company is currently facing scrutiny due to a delay in the review timeline of a drug under development, which has raised safety and efficacy concerns flagged by the U.S. Food and Drug Administration [3] Group 2: Stock Performance - Following the news of the drug review delay, Disc's stock price decreased by $6.04 per share, representing a decline of 7.84%, closing at $71.04 per share on January 15, 2026 [3] Group 3: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4]